315 related articles for article (PubMed ID: 12852794)
21. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.
Libby P; Ridker PM
Am J Med; 2004 Mar; 116 Suppl 6A():9S-16S. PubMed ID: 15050187
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting.
van der Harst P; Voors AA; Volbeda M; Buikema H; van Veldhuisen DJ; van Gilst WH
Am J Cardiol; 2006 Jun; 97(12):1697-701. PubMed ID: 16765116
[TBL] [Abstract][Full Text] [Related]
23. [C-reactive protein: cardiovascular issues of an acute-phase protein].
Amezcua-Guerra LM; Springall del Villar R; Bojalil Parra R
Arch Cardiol Mex; 2007; 77(1):58-66. PubMed ID: 17500194
[TBL] [Abstract][Full Text] [Related]
24. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
[TBL] [Abstract][Full Text] [Related]
25. Value of CRP in coronary risk determination.
Mehta JL; Sukhija R; Romeo F; Sepulveda JL
Indian Heart J; 2007; 59(2):173-7. PubMed ID: 19122252
[TBL] [Abstract][Full Text] [Related]
26. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk.
Vitale C; Gebara O; Mercuro G; Wajngarten M; Silvestri A; Rossini P; Ramires JA; Fini M; Rosano GM
Maturitas; 2005 Apr; 50(4):239-46. PubMed ID: 15780522
[TBL] [Abstract][Full Text] [Related]
27. C-reactive protein: a new golden marker of cardiovascular risk.
Gomes MC
Rev Port Cardiol; 2002 Nov; 21(11):1329-46. PubMed ID: 12564084
[TBL] [Abstract][Full Text] [Related]
28. Does high-sensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-ST elevation acute coronary syndromes?
Correia LC; Lima JC; Rocha MS; D'Oliveira Junior A; Péricles Esteves J
Clin Chim Acta; 2007 Jan; 375(1-2):124-8. PubMed ID: 16916502
[TBL] [Abstract][Full Text] [Related]
29. Combining serum biomarkers: the association of C-reactive protein, insulin sensitivity, and homocysteine with cardiovascular disease history in the general US population.
Cummings DM; King DE; Mainous AG; Geesey ME
Eur J Cardiovasc Prev Rehabil; 2006 Apr; 13(2):180-5. PubMed ID: 16575270
[TBL] [Abstract][Full Text] [Related]
30. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study).
Brodov Y; Behar S; Goldenberg I; Boyko V; Chouraqui P
Am J Cardiol; 2009 Jul; 104(2):194-8. PubMed ID: 19576345
[TBL] [Abstract][Full Text] [Related]
32. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
Anderson JL
Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
[TBL] [Abstract][Full Text] [Related]
33. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.
Delhaye C; Sudre A; Lemesle G; Maréchaux S; Broucqsault D; Hennache B; Bauters C; Lablanche JM
Cardiovasc Revasc Med; 2009; 10(3):144-50. PubMed ID: 19595394
[TBL] [Abstract][Full Text] [Related]
34. CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events?
Hedman A; Larsson PT; Alam M; Wallen NH; Nordlander R; Samad BA
Int J Cardiol; 2007 Aug; 120(1):108-14. PubMed ID: 17141340
[TBL] [Abstract][Full Text] [Related]
35. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Field KM
Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
[TBL] [Abstract][Full Text] [Related]
36. High sensitivity C-reactive protein and cardiovascular disease: an association built on unstable foundations?
Sattar N; Lowe GD
Ann Clin Biochem; 2006 Jul; 43(Pt 4):252-6. PubMed ID: 16824274
[TBL] [Abstract][Full Text] [Related]
37. Clinical correlation of multiple biomarkers for risk assessment in patients with acute coronary syndrome.
Narain VS; Gupta N; Sethi R; Puri A; Dwivedi SK; Saran RK; Puri VK
Indian Heart J; 2008; 60(6):536-42. PubMed ID: 19276492
[TBL] [Abstract][Full Text] [Related]
38. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.
Mora S; Rifai N; Buring JE; Ridker PM
Circulation; 2006 Aug; 114(5):381-7. PubMed ID: 16864722
[TBL] [Abstract][Full Text] [Related]
39. Utility of C-reactive protein measurement in risk stratification during primary cardiovascular disease prevention.
Bard RL; Rubenfire M; Eagle K; Clarke NS; Brook RD
Am J Cardiol; 2005 Jun; 95(11):1378-9. PubMed ID: 15904650
[TBL] [Abstract][Full Text] [Related]
40. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
